Highly potent PDE4 inhibitors with therapeutic potential

Bioorg Med Chem Lett. 2004 Jan 5;14(1):207-10. doi: 10.1016/j.bmcl.2003.09.087.

Abstract

Based on the hypothesis that the dose-limiting side effects of PDE4 inhibitors could be mediated via the central nervous system (CNS), design and synthesis of a hydrophilic analogue is considered to be one approach to improving the side-effect profile of Ariflo 1. Water-soluble piperidine derivatives were found to possess therapeutic potential.

MeSH terms

  • 3',5'-Cyclic-AMP Phosphodiesterases / antagonists & inhibitors*
  • 3',5'-Cyclic-AMP Phosphodiesterases / metabolism
  • Animals
  • Bronchoconstriction / drug effects
  • Bronchoconstriction / physiology
  • Cyclic Nucleotide Phosphodiesterases, Type 4
  • Cyclohexanecarboxylic Acids / adverse effects
  • Cyclohexanecarboxylic Acids / chemistry
  • Gastric Emptying / drug effects
  • Gastric Emptying / physiology
  • Guinea Pigs
  • Humans
  • Nitriles
  • Phosphodiesterase Inhibitors / chemistry*
  • Phosphodiesterase Inhibitors / pharmacology
  • Phosphodiesterase Inhibitors / therapeutic use*
  • Piperidines / chemistry
  • Piperidines / pharmacology
  • Rats
  • Tumor Necrosis Factor-alpha / biosynthesis
  • U937 Cells

Substances

  • Cyclohexanecarboxylic Acids
  • Nitriles
  • Phosphodiesterase Inhibitors
  • Piperidines
  • Tumor Necrosis Factor-alpha
  • Cilomilast
  • 3',5'-Cyclic-AMP Phosphodiesterases
  • Cyclic Nucleotide Phosphodiesterases, Type 4